REGN 250110 790.00C (REGN250110C790000) Stock Options, News & Quotes

US OptionsDetailed Quotes

REGN250110C790000

Watchlist

0.40
0.000.00%

15min DelayClose Jan 10 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,059
Moomoo News21:32 ET · Ratings
RBC Capital Sticks to Their Buy Rating for Regeneron (REGN)
TipRanks20:58 ET · Ratings
Wall Street Today: Does Anyone Have the Cash for Stargates
Kevin Travers16:05 ET
Live Stock: Stargate Rivals the Scale of the Manhattan Project, Musk Said it's a Pipe Dream
Kevin TraversJan 22 10:45 ET
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,059 From $1,184, Maintains Outperform Rating
MT NewswiresJan 22 08:23 ET · Ratings
Trump Rolls Back Effort to Lower Medicare, Medicaid Drug Costs
MarketWatchJan 21 22:33 ET

Comments

韭菜变主力

Jan 13 16:45

$Regeneron Pharmaceuticals (REGN.US)$ Wow, that was a nice dip buying. I didn’t follow their events closely. I bought back somewhat early on Jan 10.

韭菜变主力

Jan 10 13:12

$Regeneron Pharmaceuticals (REGN.US)$ It’s doing this kind of thing. Kind of scary. Nobody wants it for above 700.

韭菜变主力

Jan 7 23:51

$Regeneron Pharmaceuticals (REGN.US)$ This is in NDX and could benefit from the weakness of mega-cap tech stocks in the index.

韭菜变主力

Dec 31 16:47

$Regeneron Pharmaceuticals (REGN.US)$Nice. It’s quiet here and just broke the steep down trend.

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...